A nurse is collecting data from a client who is receiving sulfasalazine to treat ulcerative colitis. Which of the following findings should the nurse identify as an indication of an adverse effect of this medication?

Sulfasalazine is a disease-modifying anti-inflammatory medication commonly used to treat ulcerative colitis by reducing colonic inflammation. It is metabolized into active components that help suppress the inflammatory response in the gastrointestinal tract. However, because it contains a sulfonamide component, it is associated with hypersensitivity reactions and other systemic adverse effects. Nurses must closely monitor for early signs of allergic response and toxicity to prevent severe complications. Rationale: A. Constipation is not a typical adverse effect of sulfasalazine. Ulcerative colitis itself more commonly presents with diarrhea due to colonic inflammation and ulceration. Therefore, constipation would be inconsistent with both the disease process and the expected pharmacologic profile of the medication. B. Tinnitus is not a known adverse effect of sulfasalazine. It is more commonly associated with medications such as salicylates or certain aminoglycoside antibiotics. Sulfasalazine does not typically affect auditory function, making this finding unrelated to its toxicity profile. C. Rash is a significant adverse effect of sulfasalazine and may indicate a hypersensitivity reaction due to its sulfonamide component. Skin reactions can range from mild erythema to severe conditions such as Stevens-Johnson syndrome. Early recognition of rash is critical to prevent progression to life-threatening systemic reactions. D. Hypotension is not commonly associated with sulfasalazine use. The drug does not significantly affect vascular tone or blood pressure regulation. If hypotension is present, it is more likely related to other clinical conditions such as fluid loss, sepsis, or concurrent medication effects rather than this medication.